MX2015011874A - Conjugado de polimero para la administracion de un agente bioactivo. - Google Patents

Conjugado de polimero para la administracion de un agente bioactivo.

Info

Publication number
MX2015011874A
MX2015011874A MX2015011874A MX2015011874A MX2015011874A MX 2015011874 A MX2015011874 A MX 2015011874A MX 2015011874 A MX2015011874 A MX 2015011874A MX 2015011874 A MX2015011874 A MX 2015011874A MX 2015011874 A MX2015011874 A MX 2015011874A
Authority
MX
Mexico
Prior art keywords
bioactive agent
polymer
conjugates
delivery
polymer conjugate
Prior art date
Application number
MX2015011874A
Other languages
English (en)
Inventor
Andrew Craig Donohue
Adrian Sulistio
Rusell John Tait
Sarah Man Yee Ng
Stephen Lonsdale Birkett
Anton Blencowe
Original Assignee
Polyactiva Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013900883A external-priority patent/AU2013900883A0/en
Application filed by Polyactiva Pty Ltd filed Critical Polyactiva Pty Ltd
Publication of MX2015011874A publication Critical patent/MX2015011874A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Biological Depolymerization Polymers (AREA)

Abstract

La presente invención se relaciona en general con conjugados de polímero-agente bioactivo para suministrar un agente bioactivo a un sujeto. Los conjugados de polímero-agente bioactivo contienen unidades triazol en el esqueleto principal del polímero y una unidad bioactiva que se selecciona entre: análogos de prostaglandina, ß-bloqueantes y mezclas de los mismos. La presente invención se relaciona también con métodos para preparar los conjugados con el polímero usando reacciones de química click, conjugados de monómero-agente bioactivo apropiados para preparar los conjugados con el polímero, y productos farmacéuticos que comprenden los conjugados con el polímero para el tratamiento del glaucoma.
MX2015011874A 2013-03-08 2014-03-07 Conjugado de polimero para la administracion de un agente bioactivo. MX2015011874A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2013900883A AU2013900883A0 (en) 2013-03-08 Polymer conjugate for delivery of a bioactive agent
PCT/AU2014/000231 WO2014134689A1 (en) 2013-03-08 2014-03-07 Polymer conjugate for delivery of a bioactive agent

Publications (1)

Publication Number Publication Date
MX2015011874A true MX2015011874A (es) 2016-01-25

Family

ID=51490501

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011874A MX2015011874A (es) 2013-03-08 2014-03-07 Conjugado de polimero para la administracion de un agente bioactivo.

Country Status (16)

Country Link
US (2) US9572892B2 (es)
EP (1) EP2964224B1 (es)
JP (1) JP6509746B2 (es)
KR (1) KR102210895B1 (es)
CN (1) CN105358146B (es)
AU (1) AU2014225305B2 (es)
BR (1) BR112015021470B1 (es)
CA (1) CA2902372C (es)
CL (1) CL2015002462A1 (es)
HK (1) HK1220117A1 (es)
IL (1) IL241147A (es)
MX (1) MX2015011874A (es)
MY (1) MY181013A (es)
NZ (1) NZ711392A (es)
SG (1) SG11201507024VA (es)
WO (1) WO2014134689A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358146B (zh) 2013-03-08 2019-11-29 波利艾克蒂瓦有限公司 用于递送生物活性剂的聚合物缀合物
US10113033B2 (en) 2013-03-08 2018-10-30 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
US10828373B2 (en) 2015-09-10 2020-11-10 Tambo, Inc. Bioorthogonal compositions
WO2017041142A1 (en) * 2015-09-11 2017-03-16 Polyactiva Pty Ltd Polymer conjugate comprising a bioactive agent
US11071714B2 (en) 2016-04-29 2021-07-27 Children's Medical Center Corporation Poly(ketals) and related compositions and methods
IL269321B (en) * 2017-03-14 2022-07-01 Polyactiva Pty Ltd Drug-polymer conjugation that includes a prostaglandin analog conjugated to a polytriazole polymer
US11696955B2 (en) * 2017-03-14 2023-07-11 Polyactiva Pty Ltd Drug-polymer conjugate
US11207417B2 (en) * 2017-03-14 2021-12-28 Polyactiva Pty Ltd Drug-polymer conjugate
WO2018187740A1 (en) 2017-04-07 2018-10-11 Shasqi, Inc. Bioorthogonal compositions
US10606274B2 (en) 2017-10-30 2020-03-31 Nio Usa, Inc. Visual place recognition based self-localization for autonomous vehicles
CN107892660A (zh) * 2017-12-08 2018-04-10 西安近代化学研究所 1‑叠氮乙酰氧基‑2,2‑双叠氮甲基‑3‑叠氮基丙烷化合物
JP2021531269A (ja) * 2018-07-13 2021-11-18 クリスタル・デリバリー・ビー・ブイ チオシクロへプチン誘導体およびその使用
CA3154867A1 (en) * 2019-09-19 2021-03-25 Polyactiva Pty Ltd Biodegradable drug-polymer conjugate
JP7451732B2 (ja) 2020-02-06 2024-03-18 オキュラ セラピューティクス，インコーポレイテッド 眼疾患を治療するための組成物及び方法
BR112022018815A2 (pt) 2020-03-25 2022-11-29 Ocular Therapeutix Inc Implante ocular contendo um inibidor de tirosina cinase
CA3176134A1 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1044797B (it) * 1974-10-15 1980-04-21 Ferruti Paolo Alti polimeri contenenti radicali prostaglandinici processo per la loro preparazione e loro impiego
JPH03220201A (ja) 1988-11-18 1991-09-27 Eisai Co Ltd プロスタグランジン類と多糖類の結合体
US5216115A (en) 1990-06-12 1993-06-01 Rutgers, The State University Of New Jersey Polyarylate containing derivatives of the natural amino acid L-tyrosine
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US7122615B1 (en) 1998-09-10 2006-10-17 Rutgers, The State University Of New Jersey Polyanhydrides with therapeutically useful degradation products
US8158590B2 (en) * 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
WO2008128193A1 (en) 2007-04-12 2008-10-23 Rutgers, The State University Of New Jersey Biodegradable polyanhydrides with natural bioactive molecules
WO2010040187A1 (en) 2008-10-10 2010-04-15 The Bionic Ear Institute Polymer-bioactive agent conjugates
JP5746629B2 (ja) 2008-10-10 2015-07-08 ポリアクティヴァ・プロプライエタリー・リミテッド 生分解性ポリマー−生物活性部分の複合体
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
WO2010141507A1 (en) * 2009-06-01 2010-12-09 Ablitech, Inc. Biomolecule-polymer conjugates and methods of making same
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
WO2012072117A1 (en) * 2010-11-30 2012-06-07 Tomtom International B.V. Methods and systems for obtaining location information
WO2012075117A2 (en) 2010-12-01 2012-06-07 Ablitech, Inc. Small molecule-polymer conjugates and methods of making same
WO2012139164A1 (en) * 2011-04-12 2012-10-18 Polyactiva Pty Ltd Polymer conjugated prostaglandin analogues
JP5770559B2 (ja) 2011-08-04 2015-08-26 住友ゴム工業株式会社 タイヤ用ゴム組成物及びスタッドレスタイヤ
JP2013035802A (ja) * 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
CN105358146B (zh) 2013-03-08 2019-11-29 波利艾克蒂瓦有限公司 用于递送生物活性剂的聚合物缀合物
US10113033B2 (en) 2013-03-08 2018-10-30 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent

Also Published As

Publication number Publication date
BR112015021470B1 (pt) 2022-11-01
AU2014225305A1 (en) 2015-09-10
CA2902372A1 (en) 2014-09-12
IL241147A (en) 2017-11-30
KR20150126025A (ko) 2015-11-10
BR112015021470A2 (pt) 2017-07-18
CL2015002462A1 (es) 2016-02-05
SG11201507024VA (en) 2015-10-29
AU2014225305B2 (en) 2019-01-31
US9572892B2 (en) 2017-02-21
HK1220117A1 (zh) 2017-04-28
CA2902372C (en) 2021-06-15
EP2964224A1 (en) 2016-01-13
NZ711392A (en) 2020-05-29
KR102210895B1 (ko) 2021-02-02
JP2016515099A (ja) 2016-05-26
EP2964224A4 (en) 2016-11-30
US10111886B2 (en) 2018-10-30
MY181013A (en) 2020-12-16
CN105358146B (zh) 2019-11-29
US20160000929A1 (en) 2016-01-07
US20170216308A1 (en) 2017-08-03
IL241147A0 (en) 2015-11-30
WO2014134689A1 (en) 2014-09-12
CN105358146A (zh) 2016-02-24
EP2964224B1 (en) 2024-07-03
JP6509746B2 (ja) 2019-05-08

Similar Documents

Publication Publication Date Title
MY181013A (en) Polymer conjugate for delivery of a bioactive agent
PH12017500023A1 (en) Targeted conjugates and particles and formulations thereof
MX2023000076A (es) Suministro dirigido de sustancias farmacologicas que contienen amina terciaria.
MX2019000566A (es) Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña.
PH12015501385A1 (en) Autotaxin inhibitors
MX2015000821A (es) Compuestos para inmunoterapia dirigida.
NZ710746A (en) Pyrrolobenzodiazepines and conjugates thereof
MY178680A (en) Hydrogel prodrugs
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
SG194175A1 (en) Polymer conjugated prostaglandin analogues
TN2014000322A1 (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
NZ709620A (en) Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
MX2015004362A (es) Derivados de ketamina.
UA112549C2 (uk) Частинки на основі поліакрилату, що містять активну сполуку
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
BR112017028552A2 (pt) partículas e conjugados direcionados e formulações dos mesmos
MX353623B (es) Sistema de suministro de farmaco.
MX2014002780A (es) Composiciones farmaceuticas que comprenden un inhibidor de aromatasa.
MY188794A (en) Polymer conjugate comprising a bioactive agent
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof
WO2013173096A3 (en) Conjugates of huperzine and analogs thereof
GB201100804D0 (en) Drug combination

Legal Events

Date Code Title Description
FG Grant or registration